Neovii Launches Pivotal Phase 2 ATLG Study in Type 1 Diabetes, Appoints New CMO

Neovii Pharmaceuticals is advancing its FDA Fast Track-designated ATLG program into a company-sponsored pivotal Phase 2 study for Type 1 Diabetes and has appointed Salvatore Alesci as Chief Medical Officer to lead the effort.

Chicago Metrowire Staff
••Healthcare
Neovii Launches Pivotal Phase 2 ATLG Study in Type 1 Diabetes, Appoints New CMO

Neovii Pharmaceuticals AG, a Swiss-headquartered commercial-stage biopharmaceutical company with over four decades of experience in antibody-based immunotherapies, has announced a significant expansion of its Type 1 Diabetes (T1D) clinical program. The company is moving forward with a company-sponsored pivotal Phase 2 study of anti-T-lymphocyte globulin (ATLG) in the United States and European Union, building on an ongoing investigator-initiated European study known as GIRO (Grafalon in early onset). The announcement, first reported via NEWMEDIAWIRE, signals Neovii’s strategic push beyond transplantation into autoimmune and immune-mediated diseases.

The ATLG program has received FDA Fast Track designation for the prevention of declining C-peptide production in patients with recent-onset T1D. Fast Track status is designed to facilitate the development and expedited review of therapies that address serious conditions with unmet medical need. While the designation does not guarantee approval or Accelerated Approval, it underscores the regulatory recognition of ATLG’s potential in T1D. Patients have already been treated in the GIRO study, and a 12-month efficacy and safety interim analysis is expected to provide a near-term milestone that will inform the pivotal trial design and regulatory discussions with the FDA, European authorities, and other health agencies.

The scientific rationale for ATLG in T1D rests on the disease’s autoimmune nature. T1D is characterized by T-cell-mediated destruction of insulin-producing pancreatic beta cells, and many patients retain residual beta-cell function after diagnosis. Preserving that endogenous function remains a key therapeutic goal. ATLG is a polyclonal anti-T-lymphocyte globulin with preferential activity against activated T cells and broader effects on immune pathways involved in autoimmune responses. Published clinical proof of concept by Saudek et al. in a placebo-controlled study of recent-onset T1D, together with other evidence, supports evaluating ATLG in the GIRO and pivotal Phase 2 studies. ATLG has been used in transplantation medicine for more than four decades, and Neovii is leveraging that extensive manufacturing and clinical experience to assess its potential in autoimmune disease.

In conjunction with the program expansion, Neovii has appointed Salvatore “Salvo” Alesci, M.D., Ph.D., as Chief Medical Officer, effective October 15, 2026. Dr. Alesci is a physician-scientist with more than 25 years of experience in endocrinology, immunology, translational medicine, clinical development, and regulatory strategy. He will lead Neovii’s medical and clinical development activities, oversee the T1D program, and help shape the company’s broader clinical strategy. Frederic Prince, Ph.D., Chief Executive Officer of Neovii, said the appointment brings valuable expertise as the company advances its T1D program and evaluates future opportunities in immune-mediated diseases. Dr. Alesci said he looks forward to working with investigators, patients, advocacy groups, and regulators to execute a rigorous development program.

For Neovii, the move represents a notable evolution from its established transplantation business—anchored by Grafalon® (ATLG), approved in multiple countries and commercialized in more than 50 countries—into the larger arena of autoimmune disease. The company’s decision to fund a pivotal Phase 2 study in both the U.S. and EU, informed by GIRO data, could position ATLG as a differentiated immunomodulatory approach for T1D if results are positive. More details are available in the original release. ATLG remains investigational in T1D and has not been approved for this use.

Blockchain Registration

QR Code for Blockchain Registration